SRPT•benzinga•
Sarepta Therapeutics Granted FDA Platform Technology Designation For rAAVrh74 Viral Vector Used In Investigational Gene Therapy SRP-9003 For Treatment Of Limb-Girdle Muscular Dystrophy Type 2E/R4
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga